Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.

March 31, 2015

Improving Standard of Care Through Variety

Alexander Bastian says the most important thing to come out of ASH that will improve standard of care is the variety of treatments coming available, including a new drug from Amgen for treating ALL.

October 16, 2015

A Look Into Anti-PD-1 and Anti-PD-L1 Therapies

Dr. Sanjiv Agarwala analyzes anti-PD-1 and anti-PD-L1 therapies in terms what they do and their unique toxicities and response patterns.